Clinical Trial: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional



Official Title: A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent

Brief Summary:

  1. CBT-001 administered three times daily (TID) for 4 weeks has an acceptable safety profile when used in pterygium patients
  2. CBT-001 administered TID for 4 weeks is more effective than the vehicle in reducing pterygium vascularity and inhibiting pterygium lesion growth
  3. CBT-001 administered as topical ocular dosing displays negligible systemic drug exposure